Optimizing the Duration of Assessment of Stage-1 Sacral Neuromodulation in Nonobstructive Chronic Urinary Retention

Authors

  • Sohier Elneil PhD, MRCOG,

    Corresponding author
    1. Department of Uro-neurology, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    • Address correspondence to: Sohier Elneil, PhD, MRCOG, Department of Uro-Neurology, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Email: sohier.elneil@uclh.nhs.uk

    Search for more papers by this author
  • Bahareh Abtahi Pharm D,

    1. Department of Uro-neurology, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    Search for more papers by this author
  • Mohamed Helal PhD (Urology),

    1. Department of Uro-neurology, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    Search for more papers by this author
  • Alex Digesu PhD, MRCOG,

    1. Department of Urogynaecology, St Mary's Hospital, Imperial College Healthcare, NHS Trust, London, UK
    Search for more papers by this author
  • Gwen Gonzales RGN

    1. Department of Uro-neurology, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    Search for more papers by this author

  • Conflict of Interest: There is no conflict of interest to declare other than Dr. Elneil works as a Consultant to Medtronic and Miss Gonzales has run a trial for Medtronic.
  • For more information on author guidelines, an explanation of our peer review process, and conflict of interest informed consent policies, please go to http://www.wiley.com/bw/submit.asp?ref=1094-7159&site=1
  • Source(s) of financial support: Not applicable.

Abstract

Objectives

The duration of test stimulation using two-stage sacral neuromodulation (SNM) is not studied. This study will determine the restoration of normal bladder sensation and resultant voiding in chronic urinary retention (CUR) after stage-1 SNM.

Materials and Methods

Two-stage SNM used in 24 female patients with CUR. After stage-1 SNM, patients were assessed over an eight-week period and asked to record the restoration of normal bladder sensation and voiding. Qualitative and quantitative statistics were used to assess the outcomes and the influence of prognostic factors.

Results

The mean age of patients was 37.0 ± 9.7 years. Normal bladder sensation was restored on the same day as switching on the battery after stage-1 in seven patients (29.2%), while in 17 patients it occurred between day 2–31 (mean: nine days). Similarly, the mean onset of voiding was also nine days (range: 2–31 days). After day 15, 21% of patients voided. The mean lag time between the restoration of bladder sensation and voiding was 3.6 days. By day 17, a cumulative percentage of 90% of patients had a normalized bladder sensation and 80% had commenced voiding. Infection of the externalized lead occurred in only one case. There were no correlations between the outcome parameters with age (p > 0.05), symptom duration, or concomitant diagnosis of overactive bladder or chronic pelvic pain (p = 0.418, p = 0.114).

Conclusion

Stage-1 SNM may be left in situ for up to four weeks to ensure the maximum chance of restoring normal bladder function in this complex group of patients.

Ancillary